The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines advise against starting ESAs when Hb levels are ≥10.0 g/dl, using ESA to maintain Hb >11.5 g/dl and intentionally increasing Hb to >13 g/dl [8], but suggest aiming for a higher Hb level in individual patients to improve QoL if the benefits outweigh the risks [8]. The gene discussed is GSTM1; the disease is kidney disorder.